n-3 polyunsaturated fatty acids abrogate mTORC1/2 signaling and inhibit adrenocortical carcinoma growth in vitro and in vivo

JUN LIU1,2*, MEINIAN XU3*, YONGBIN ZHAO1, CHUNPING AO3, YUKUN WU3, ZHENGUO CHEN3, BANGQI WANG1, XIAOCHUN BAI3, MING LI3 and WEILIE HU1

1Department of Urology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou 510010; 2Guangzhou Huabo Bio-Pharmaceutical Research Institute, Guangzhou 510010; 3Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China

Received December 10, 2015; Accepted January 6, 2016

DOI: 10.3892/or.2016.4720

Abstract. n-3 polyunsaturated fatty acids (PUFAs) are essential for human health and have been reported to reduce the risk of cancer, inhibit the growth of various types of tumors both in vitro and in vivo, and affect adrenal function. However, their effects on adrenocortical carcinoma (ACC) are not known. In the present study, we demonstrated that docosahexenoic acid (DHA) inhibited ACC cell proliferation, colony formation and cell cycle progression, and promoted apoptosis. In addition, ectopic expression of fat-1, a desaturase that converts n-6 to n-3 PUFAs endogenously, also inhibited ACC cell proliferation. Moreover, supplementing n-3 PUFAs in the diet efficiently prevented ACC cell growth in xenograft models. Notably, implanted ACC cells were unable to grow in fat-1 transgenic severe combined immune deficiency mice. Further study revealed that exogenous and endogenous n-3 PUFAs efficiently suppressed both mTOR complex 1 (mTORC1) and mTORC2 signaling in ACC in vitro and in vivo. Taken together, our findings provide comprehensive preclinical evidence that n-3 PUFAs efficiently prevent ACC growth by inhibiting mTORC1/2, which may have important implications in the treatment of ACC.

Introduction

Adrenocortical carcinoma (ACC) is a rare, highly aggressive endocrine malignancy derived from cells of the adrenal cortex and is often accompanied by unfavorable prognosis (1,2). Despite significant advances in the last decade, its pathogenesis is only incompletely understood and overall therapeutic means are unsatisfactory (3). Therefore, it is urgent to find new treatment targets for ACC.

ω-3 (n-3) and ω-6 (n-6) polyunsaturated fatty acids (PUFAs) are essential fatty acids necessary for human health. Epidemiological studies suggest that diet with a high n-6/n-3 ratio contributes to cardiovascular disease, inflammation and cancer (4-6), while consumption of more fish or fish oil with a high n-3/n-6 ratio could reduce the risk of colon, prostate and breast cancers (7,8). Laboratory and animal studies have shown that n-3 PUFAs inhibit the growth of various types of cancers both in vitro and in vivo and affect emotions through the hypothalamic-pituitary-adrenal (HPA) axis (9,10), as well as catecholamine handling through adrenal chromaffin cells (11), suggesting that n-3 PUFAs may affect adrenal structure and function. However, the effect of n-3 PUFAs on ACC is not known.

Mammalian target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase composed of two functionally distinct signaling complexes, mTOR complex 1 (mTORC1) and complex 2 (mTORC2) (12). mTOR is a key molecule for controlling cell growth, proliferation, survival and metabolism (12,13). Upregulation of mTOR signaling has been found in many cancers and is thought to play important roles in carcinogenesis and tumor progression (14-16). The mTOR pathway is also activated in a subset of adrenal tumors, but its role remains unclear.

We previously developed a transgenic mouse model that expresses fat-1, a desaturase that converts n-6 PUFAs to n-3 PUFAs and have applied it to study the effects of n-3 PUFAs on breast cancer (17,18). In the present study, we investigated the potential effects of exogenous and endogenous n-3 PUFAs...
on the growth of ACC cell lines and tumor xenografts and explored the possible signaling mechanisms.

Materials and methods

Materials. All cell culture reagents were obtained from Gibco-BRL Life Technologies (Grand Island, NY, USA). Arachidonic acid (AA) and docosahexaenoic acid (DHA) were obtained from Cayman Chemical (Ann Arbor, MI, USA) and prepared as dimethyl sulfoxide (DMSO) stock solutions following the manufacturer's instructions. Insulin, primary antibody against β-actin and HRP-conjugated anti-mouse and anti-rabbit IgG were from Sigma (St. Louis, MO, USA). Primary antibodies against phospho-S6 (S235/236) were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-S6, phospho-Akt (S473) and Akt antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). pST180 control vector and pST180-fat-1 vector were chemically synthesized by GenePharma Co., Ltd. (Shanghai, China).

Cell lines and culture conditions. The human ACC cell lines SW13 and H295R were used in the present study. SW13 was preserved in our laboratory in L-15 supplemented with 10% fetal bovine serum (FBS) (Invitrogen Corp., Grand Island, NY, USA) and cultured in a 37°C humidified atmosphere containing 100% air and no CO2. The H295R cell line was obtained from the Cell Center of the Chinese Academy of Sciences, maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% FBS and cultured in a 37°C humidified atmosphere containing 95% air and 5% CO2. Cells were trypsinized upon confluency and propagated to passage 2 before being subcultured in 6-, 12- or 96-well plates for the experiments.

Cell proliferation assay. Cells were seeded at 2x10^3 cells/well in 96-well plates. After being cultured in medium containing 10% FBS for 24 h, the cells were treated with DHA at different concentrations (10-80 µM) for 72 h with refreshing every 24 h. Cell viability was then assessed using Cell Counting kit-8 (CCK-8) (cat no. kGA317; keyGen biotech, Nanjing, China) according to the manufacturer's instructions. Apoptotic cells were identified as dark brown nuclei under a light microscope. The number of apoptotic cells was counted in five random fields (magnification, x400) in a blinded manner.

Western blot analysis. Protein expression levels were determined by western blot analysis as previously described (20). Briefly, after treatment for the indicated time, cells were lysed immediately in Laemmli buffer (62.5 mM Tris- HCl pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.01% bromophenol blue) for 5 min at 95°C. Cell lysates were resolved by SDS/PAGE and transferred electrophoretically to nitrocellulose membranes (Bio-Rad). The membranes were incubated with specific antibodies and immunoreactive proteins were revealed using an enhanced chemiluminescence (ECL) kit (Santa Cruz Biotechnology, Inc.).

Apoptosis assessment of cells and tissues. The Annexin V-FITC apoptosis detection kit was used for the apoptosis assay (KeyGen Biotech). In brief, SW13 cells (1x10^6 cells/ml) were treated with 25 µM DHA for 12 h, harvested by trypsinization, washed twice with phosphate-buffered saline (PBS), and resuspended in 500 µl of binding buffer. The cells were then incubated with 5 µl of Annexin V-FITC and 5 µl of propidium iodide (PI) for 10 min at room temperature in the dark and evaluated immediately by flow cytomtery (FACSCalibur).

Xenografts in nude mice. Four-week-old female nude mice were purchased from the Experimental Animal Center of Southern Medical University (Guangzhou, China) and housed in a specific pathogen-free facility in accordance with guidelines established by the Committee on Animal Research of the Southern Medical University. SW13 cells at early passages were harvested, prepared as 3x10^6 cells/100 µl PBS suspension and implanted subcutaneously into the right flanks of each mouse. The animals were then randomly assigned into two groups with 6 mice each and fed with a normal (low) or high n-3 PUFA diet (21). Bidimensional tumor measurements were taken every 2 days. Tumor volume (V) was calculated as: V = 0.52 (length x width^2). On day 29 after SW13 cells were implanted, all animals were sacrificed and the tumors were collected and weighed. The volume of the excised tumors was calculated as: V = 0.52 (length x width x depth). Various tumor specimens were minced and lysed for western blot analysis, while others were fixed in 4% formaldehyde, embedded in
paraffin and cut in 4-µm sections for immunohistochemical analysis.

**Xenografts in severe combined immune deficiency (SCID) and fat-1-SCID mice.** Homozygous SCID mice (Jax no. 001131) (bALb/c background) were bred with fat-1 transgenic mice (originally on the C57bL/6 background) produced previously to generate fat-1-SCID double-hybrid mice. These mice were backcrossed with b ALb/c mice for 10 generations. Female littermates lacking the fat-1 transgenic gene were used as controls. DNA extractions from the tail tips of offspring were subjected to PCR for genotyping in accordance with the protocol on the Jackson Laboratory webpage, using primers listed in Table I. Four-week-old female homozygous SCID mice (n=6) with or without the fat-1 gene were injected with 100 µl (1x10³) of the SW13 cell suspension and were subjected to bidimensional tumor measurement and tumor sample analysis as described above.

**Immunohistochemistry.** Tumor allografts were removed. After being weighed, they were immediately fixed in 2.5% glutaraldehyde-poloxymethylene solution and processed as paraffin sections using a standard method. Three sequential sections (5 µm) of each sample were used for hematoxylin and eosin (H&E) staining, immunohistochemical (IHC) detection of phospho-S6 (S235/S236) (1:300; Cell Signaling Technology) and IHC detection of phospho-Akt (S473) (1:100; Santa Cruz biotechnology, Inc.), respectively. Cells with yellow brown cytoplasm or nuclei were considered positive. The percentage of positive cells was calculated after counting 1,000 cells at higher magnification (x400) according to the following formula: Percentage of positive cells = (number of positive cells/number of total cells) x 100%.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward (5’→3’)</th>
<th>Reverse (5’→3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>fat-1</td>
<td>GGACCTGGTGAAAGGCATCCG</td>
<td>GCCGTCGTCAGAGCCTCAAC</td>
</tr>
<tr>
<td>SCID</td>
<td>GAAAAGAATTGGTATCCAC</td>
<td>AGTTAACCAGCTGGTTGCC</td>
</tr>
</tbody>
</table>

**Statistical analysis.** Statistical analyses were performed using SPSS (version 13.0). Data are presented as mean ± SD of at least three independent experiments. Differences between two
groups were analyzed using the Student's t-test, and differences among more than two groups were analyzed using one-way ANOVA and post hoc LSD tests. A $P<0.05$ was considered as statistically significant. In the case of western blot analysis, one representative set of data is shown.

Results

n-3 PUFAs inhibit ACC cell proliferation and colony formation and induce G0/G1 cell cycle arrest. To investigate the potential protective role of n-3 PUFAs against ACC, we examined the effect of DHA on the proliferation of ACC cell lines. We treated SW13 and H295R cells with various concentrations (0-100 µM) of DHA and assessed the effects after 48 h of treatment. As shown in Fig. 1A and B, DHA significantly inhibited the proliferation of both ACC cell lines in a dose-dependent manner. Transgenic expression of fat-1 is capable of converting n-6 PUFAs to n-3 PUFAs, leading to an increase in the amount of n-3 PUFAs and a decrease in the n-6/n-3 ratio. In addition, SW13 cells were transfected with the fat-1 or control vector, and cell viability was assessed 48 h later. As expected, the proliferation rate of the fat-1-expressing cells was significantly decreased by almost 40% compared with that noted in the control cells (Fig. 1C). Together, these findings demonstrate that both exogenous and endogenous n-3 PUFAs are effective to inhibit ACC cell proliferation.

We next examined the effects of DHA on cell colony formation of ACC cells. Our results showed that DHA prevented colony formation of the ACC cells in a dose-dependent manner. When used at 5 µM DHA, DHA inhibited the cell colony formation of the SW13 and H295R cells by 60 and 50%, respectively. Additionally, 20 µM DHA decreased the colony formation of the SW13 and H295R cells by 97 and 75%, respectively, compared with the control (Fig. 1D and E).

Dietary n-3 PUFAs inhibit the growth of ACC xenografts in nude mice. After showing the inhibitory effects of n-3 PUFAs on the proliferation of ACC cells, we examined the ability of n-3 PUFAs to inhibit tumor growth in vivo. We established an ACC xenograft model by subcutaneously implanting SW13 cells into nude mice. The animals were administered a normal (low) or high n-3 PUFA diet. As shown in Fig. 2, a high n-3 PUFA diet efficiently prevented tumor growth and reduced the average tumor weight and volume. Fatty acid composition analysis identified a significantly increased ratio of n-3/n-6 PUFAs in the tumors of mice fed a high n-3 PUFA diet when compared with that of mice fed a normal diet (Table II).

Endogenously produced n-3 PUFAs inhibit the growth of ACC xenografts in SCID mice. Transgenic expression of fat-1...
is capable of converting n-6 PUFAAs to n-3 PUFAAs, leading to an increase in n-3 PUFAAs and a decrease in the n-6/n-3 ratio, and allows us to perform well-controlled studies in the absence of restricted diets. For this purpose, we previously established fat-1 transgenic SCID mice and confirmed that the ratio of n-3/n-6 PUFAAs in the fat-1 transgenic SCID mice is significantly increased compared with this ratio in the wild-type (WT) SCID mice lacking fat-1 expression (22). Notably, although xenograft tumors with an average volume of 473 mm$^3$ were observed within 4 weeks in the control SCID mice, we failed to observe tumor growth in any of the fat-1 SCID mice (Fig. 3), suggesting that ACC cells are unable to proliferate or survive in the presence of high levels of endogenously produced n-3 PUFAAs in vivo.

n-3 PUFAAs promote ACC cell apoptosis both in vitro and in vivo. We further examined whether n-3 PUFAAs could induce ACC cell apoptosis in vitro and in xenografts. The results showed that DHA significantly increased the number of apoptotic cells in serum-starved SW13 cells but not in SW13 cells cultured with normal FbS (Fig. 4A and b), suggesting that DHA promotes ACC cell apoptosis in vitro. The effect of n-3 PUFAAs on apoptosis was further examined in xenograft models. The results revealed that administration of n-3 PUFAAs promoted xenografted ACC tumor apoptosis as manifested by the increased numbers of TUNEL-positive tumor cells in mice fed a high n-3 PUFA diet (Fig. 4C and D). We conclude that n-3 PUFAAs promote ACC cell apoptosis both in vitro and in vivo.

n-3 PUFAAs inhibit mTORC1/2 signaling in ACC cell lines and a xenograft mouse model. To investigate the underlying mechanisms of the in vitro effect of n-3 PUFAAs on mTORC1/2 signaling, we first examined whether DHA (exogenous n-3 PUFAAs) inhibited mTORC1/2 in the ACC cells. In the SW13 cells, DHA rapidly and dose-dependently suppressed insulin-stimulated mTORC1-directed phosphorylation of S6 (S235/235) and mTORC2-directed phosphorylation of Akt (S473) (Fig. 5A). We next examined the role of endogenously produced n-3 PUFAAs in mTORC1/2 signaling. In the SW13 cells transfected with fat-1 cDNA, phosphorylation of S6 (S235/235) and Akt (S473) was significantly reduced compared with the cells transfected with the control vector (Fig. 5B). These results suggest that both the mTORC1 and mTORC2 signaling pathways are targets of exogenous and endogenous n-3 PUFAAs in ACC cells.

### Table II. Fatty acid composition in the nude mouse tumors.

<table>
<thead>
<tr>
<th>Type of fatty acids</th>
<th>n-3 PUFA diet</th>
<th>n-6 PUFA diet</th>
</tr>
</thead>
<tbody>
<tr>
<td>(mol % of total fatty acid)</td>
<td>Normal</td>
<td>High</td>
</tr>
<tr>
<td>C18:3 n-3, α-linoleic acid</td>
<td>0.25±0.12</td>
<td>0.44±0.08</td>
</tr>
<tr>
<td>C20:5, n-3, eicosapentaenoic acid (EPA)</td>
<td>0.13±0.02</td>
<td>0.96±0.05</td>
</tr>
<tr>
<td>C22:5, n-3, docosapentaenoic acid (DPA)</td>
<td>0.56±0.11</td>
<td>1.23±0.14</td>
</tr>
<tr>
<td>C22:6, n-3, docosahexaenoic acid (DHA)</td>
<td>2.15±0.38</td>
<td>4.37±0.33</td>
</tr>
<tr>
<td>n-3, total</td>
<td>3.08±0.33</td>
<td>7.00±0.40</td>
</tr>
<tr>
<td>C18:2, n-6, linoleic acid</td>
<td>19.24±3.12</td>
<td>17.32±2.17</td>
</tr>
<tr>
<td>C20:4, n-6, arachidonic acid (AA)</td>
<td>1.75±0.37</td>
<td>1.22±0.18</td>
</tr>
<tr>
<td>n-6, total</td>
<td>20.99±2.92</td>
<td>18.55±2.08</td>
</tr>
<tr>
<td>n-3/n-6</td>
<td>0.15±0.02</td>
<td>0.38±0.04</td>
</tr>
</tbody>
</table>

Values of n-3 and n-6 in mammary tumors (n=6) were measured by gas chromatography-mass spectroscopy. Data indicate mean ± SD. *P<0.01, compared with a normal n-3 PUFA diet. PUFAAs, polyunsaturated fatty acids.
We next determined whether n-3 PUFAs could suppress mTORC1/2 in vivo. The levels of mTORC1/2 signaling in the excised tumors of the different groups were examined by immunohistochemical staining and western blotting. As shown in Fig. 5C, a high n-3 PUFA diet decreased the percentage of p-S6 (S235/236) and p-Akt (S473)-positive cells. Western blot analysis also showed that a high n-3 PUFA diet resulted in a significant reduction in levels of phosphorylated S6 (S235/236) and Akt (S473) (Fig. 5D). These data suggest that mTORC1 and mTORC2 signaling are the targets of n-3 PUFAs in vivo and suppression of mTORC1/2 signaling by n-3 PUFAs may contribute to their inhibitory effects on ACC tumor growth.

**n-6 PUFAs activate mTORC1 signaling in ACC cells and stimulate ACC cell proliferation.** Several previous studies have shown that arachidonic acid (AA) and its metabolites stimulate the growth and proliferation of various tumor cells (6,23-25), suggesting that n-6 PUFAs may have opposite effects on cancer when compared with n-3 PUFAs. However, whether AA has any effect on ACC cell proliferation has not been reported. As shown in Fig. 6B, AA dose-dependently stimulated SW13 cell proliferation from 0.1 to 5 µM, and increased mTORC1-directed phosphorylation of S6 (S235/236) and Akt (S473) (Fig. 6D). These data suggest that mTORC1 and mTORC2 signaling are the targets of n-3 PUFAs in vivo and suppression of mTORC1/2 signaling by n-3 PUFAs may contribute to their inhibitory effects on ACC tumor growth.

**Figure 4. n-3 PUFAs promote ACC cell apoptosis in vitro and in vivo.** (A) Shown are the representative images of flow cytometric analysis of SW13 cells cultured in medium with or without 10% FBS. Cells were treated with 25 µM DHA or without DHA for 12 h, stained with Annexin V-FITC and PI and immediately subjected to flow cytometry. (B) The percentage of apoptotic cells in each group. Bars indicate mean ± SD. Statistics were performed by one-way ANOVA with application of LSD post test. *P<0.05 and #P>0.05, compared with the respective controls. (C) Nude mice injected with a suspension of SW13 cells were administered a normal (Con) or high n-3 PUFA diet for 29 days and analyzed using DeadEnd™ Colorimetric TUNEL System. The number of apoptotic cells in five random fields (magnification, x400) was counted in a blinded manner. Bars indicate mean ± SD. *P<0.05, compared with the control by Student's t-test. (D) Representative images of tumor sections examined by TUNEL assay. Apoptotic cells were identified as dark brown nuclei under a fluorescence microscope (magnifications, x100 and x400).
Discussion

The present study, for the first time, investigated the roles of n-3 PUFAs in the growth of ACC using in vitro cultured cells and an animal model. We found that DHA, a n-3 PUFA, exhibits strong anticancer activity in human ACC cells through a combination of multiple actions, including inhibition of cell proliferation and cell cycle progression and induction of cell apoptosis. The strong anticancer effect was also observed in vivo in tumor-bearing mice. All this evidence indicates that exogenous and endogenous n-3 PUFAs inhibit ACC cell growth both in vitro and in vivo.

Although increasing evidence from animal and in vitro studies indicate that n-3 PUFAs present in fatty fish and fish oils inhibit the carcinogenesis of many types of tumors, inconsistencies remain (4,21). Several factors may account for these inconsistent results including: i) a wide variations in the amount and source of n-3 PUFAs consumed in each study; and ii) the ratio of n-6 to n-3, which may be more important than the absolute amount of n-3 PUFAs, as suggested by animal and human studies (6). Transgenic expression of fat-1 enables the host to produce n-3 PUFAs endogenously while concomitantly reducing the levels of n-6 PUFAs (17,21). In addition, the fat-1 transgenic mouse is capable of increasing n-3 content with a balanced n-6/n-3 PUFA ratio in all tissues and allows carefully controlled studies to be performed in the absence of restricted diets (17,21). We found that ACC cells did not grow at all in fat-1 transgenic SCID mice possibly since the transplanted cells the in fat-1 transgenic SCID mice underwent growth inhibition and apoptosis after uptaking n-3 PUFAs from their immediate environment. Due to the lack of a reagent available to induce adrenal tumorigenesis and a genetically induced animal model with adrenal tumorigenesis, it was not possible for us to investigate whether n-3 PUFAs have any effect on adrenal carcinogenesis and progression. However, we can conclude from our results that exogenous...
LIU et al: n-3 POLYUNSATURATED FATTY ACIDS INHIBIT ADRENOCORTICAL CARCINOMA

and endogenous n-3 PUFAs can inhibit ACC growth both in vitro and in vivo.

Understanding n-3 PUFA-regulated signaling pathways in cancer may provide valuable information for assessing their potential value in both cancer prevention and treatment. We found that exogenous and endogenous n-3 PUFAs inhibited mTORC1 and mTORC2 signaling in the ACC cells and in the tissues of tumor-bearing mice. mTOR is a key molecule which integrates diverse signals including nutrients, growth factors, energy and stresses to control cell growth, proliferation, survival and metabolism (12,13). mTOR signaling is upregulated in many types of cancers and plays key roles in the carcinogenesis and progression of these diseases, thus it is regarded as a key target for cancer therapy (14-16). mTORC1 inhibitors such as rapamycin and enviroolum have been used for the treatment of ACC in preclinical trials, but the results were not promising (26). The reason is that these drugs only block mTORC1 and have little effect on mTORC2, which has a feedback effect on mTORC1 signaling (20). The development of dual inhibitors of mTORC1 and mTORC2 may obviate this issue since they appear to exhibit a superior effect in tumor treatment than inhibitors of mTORC1 only (27). Our findings that n-3 PUFAs target both mTORC1 and mTORC2 pathways may explain their strong inhibitory effects on ACC in vitro and in vivo. The mechanisms by which n-3/n-6 PUFAs regulate mTORC1/2 remain to be identified.

We previously reported that AA-activated mTOR signaling plays a critical role in breast carcinogenesis and angiogenesis (25). Not surprisingly, in the present study, we also found that AA activated mTOR signaling in ACC cells and promoted ACC cell proliferation, which requires activation of the mTORC1 signaling pathway. Unfortunately, no animal model, which can mimic ACC development, can be used to explore the effects of n-6 PUFAs on adrenal carcinogenesis. Our results at least showed that n-6 PUFAs may be related to ACC growth and upregulation of mTOR signaling in ACC may be partly due to AA uptake. It has been reported that prostate or breast-specific knockout of TSC1 (which activates mTORC1) can lead to prostate or breast carcinogenesis (28,29). Therefore, we can use the adrenal cortical-specific Cre mouse and TSC1-loxp mouse to investigate whether adrenal mTORC1 activation could lead to adrenal hyperplasia, adenoma formation or ACC development and confirm the role of mTORC1 in adrenal carcinogenesis (30).

In conclusion, our results indicate that both endogenously synthesized and exogenously uptaken n-3 PUFAs inhibit ACC growth, while n-6 PUFAs have an opposite effect, the mechanisms of which may be mediated by mTORC1/2 signaling. However, further research is required to investigate the key role of mTORC1/2 signaling in adrenal carcinogenesis. In addition, future research must elucidate whether n-6 PUFA intake has any direct relationship with mTOR signaling activation in ACC.

Acknowledgements

The present study was supported by the National Natural Sciences Foundation of China (nos. 81302230 and 31371186), the China Postdoctoral Science Foundation (2013M542159), the Natural Science Foundation of Guangdong Province, China (2014A030313296), and the Guangdong Province Outstanding Young Teacher Training funds.

References